MyeTRIAL Partnership

Project aim

This partnership builds on our existing relationship and the transformational achievements of the Concept, Access and Research Programme (CARP), funded by Myeloma UK, which helped to accelerate the development of new myeloma treatments. MyeTRIAL will further improve and extend the lives of people with myeloma by driving innovative clinical research developed in partnership with the myeloma community.  

By bringing together real-world experience, specialist knowledge, and world-class clinical trials expertise, the programme will: 

• Focus on what matters most: People living with myeloma and those who support them know the questions that truly need answers. Their priorities will shape every step we take. 

• Make sure nobody is left behind: Everybody deserves access to better treatment and better outcomes. We’ll work with the best researchers and support new talent so that breakthroughs reach every part of the myeloma community. 

• Make every discovery count: Research should change lives. We’ll share our learning, so people with myeloma everywhere can benefit. 

How will this partnership help people living with myeloma? 

Clinical trials are essential for developing new treatments, improving our understanding of myeloma, and generating the evidence needed for therapies to be approved on the NHS. However, too often the priorities and lived experiences of patients are not placed at the centre of trial design.  

By ensuring people affected by myeloma are involved in clinical trial development from day one, MyeTRIAL can ensure trials better address the real challenges people face and prioritise the things that matter most.  

“Our vision is to improve and extend the lives of people with myeloma, by driving innovative clinical research developed with patients and for patients.” 

MyeTRIAL is committed to designing and delivering clinical trials that make a meaningful difference to people living with myeloma. It focuses on addressing real unmet needs and the everyday challenges faced by patients and carers.  

Curing myeloma remains the most important goal for people living with myeloma. Part of our work will focus on evaluating new therapies and approaches to care and ensuring patients get earlier access to promising new treatments in early phase trials. 

Living with myeloma brings many other important challenges. We will develop trials that focus on the issues patients and carers say matter most in everyday life, while promoting more equitable access to clinical trials so that everyone has the opportunity to take part, regardless of who they are or where they live.  

Rather than directly funding individual clinical trials, MyeTRIAL maximises the impact of our investment by supporting a dedicated team of experts who help researchers across the UK design more and better trials from the very beginning, using the latest knowledge on how to run the very best trials. They also help secure funding from larger organisations, including pharmaceutical companies and public and third sector funders. This approach accelerates progress for far more people than any single trial could. 

This approach puts our 2025–2029 Research Strategy into action by embedding strategic studies within larger trials to address issues that matter most to patients, reduce clinical and demographic barriers to participation, and promote best practice in myeloma clinical trial design. 

How can I get involved? 

The MyeTRIAL Partnership will work closely with the myeloma community in a variety of ways to understand priorities for research and clinical trials and to co-design these together.

To hear about opportunities to get involved, please sign up to our newsletter, or our Spotlight newsletter if you are a healthcare professional, and follow us on social media.